Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 414

1.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; SONAR Committees and Investigators.

Lancet. 2019 Apr 12. pii: S0140-6736(19)30772-X. doi: 10.1016/S0140-6736(19)30772-X. [Epub ahead of print]

PMID:
30995972
2.

Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.

Pollock C, Stefánsson B, Reyner D, Rossing P, Sjöström CD, Wheeler DC, Langkilde AM, Heerspink HJL.

Lancet Diabetes Endocrinol. 2019 Apr 12. pii: S2213-8587(19)30086-5. doi: 10.1016/S2213-8587(19)30086-5. [Epub ahead of print]

PMID:
30992195
3.

Correction to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB.

Diabetologia. 2019 May;62(5):873. doi: 10.1007/s00125-019-4845-x.

PMID:
30899969
4.

Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.

Rotbain Curovic V, Theilade S, Winther SA, Tofte N, Eugen-Olsen J, Persson F, Hansen TW, Jeppesen J, Rossing P.

Diabetes Care. 2019 Mar 18. pii: dc181427. doi: 10.2337/dc18-1427. [Epub ahead of print]

PMID:
30885954
5.

Uric Acid is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Event and Mortality in Patients With Type 1 Diabetes.

Pilemann-Lyberg S, Hansen TW, Tofte N, Winther SA, Theilade S, Ahluwalia TS, Rossing P.

Diabetes Care. 2019 Mar 18. pii: dc182173. doi: 10.2337/dc18-2173. [Epub ahead of print]

PMID:
30885950
6.

Cardiac Autonomic Function is Associated With Myocardial Flow Reserve in Type 1 Diabetes.

Zobel EH, Hasbak P, Winther SA, Stevns C, Fleischer J, von Scholten BJ, Holmvang L, Kjaer A, Rossing P, Hansen TW.

Diabetes. 2019 Mar 12. pii: db181313. doi: 10.2337/db18-1313. [Epub ahead of print]

PMID:
30862683
7.

A marker of type VI collagen formation (PRO-C6) is associated with higher arterial stiffness in type 1 diabetes.

Frimodt-Møller M, Hansen TW, Rasmussen DGK, Theilade S, Nielsen SH, Karsdal MA, Genovese F, Rossing P.

Acta Diabetol. 2019 Mar 9. doi: 10.1007/s00592-019-01306-9. [Epub ahead of print] No abstract available.

PMID:
30852680
8.

Diagnosis of diabetic kidney disease: state of the art and future perspective.

Persson F, Rossing P.

Kidney Int Suppl (2011). 2018 Jan;8(1):2-7. doi: 10.1016/j.kisu.2017.10.003. Epub 2017 Dec 29. Review.

9.

Increasing ESKD in Diabetes in the Land Down Under: What Can Be Done, We Must Wonder.

Rossing P, Frimodt-Møller M, Persson F.

Am J Kidney Dis. 2019 Mar;73(3):293-296. doi: 10.1053/j.ajkd.2018.11.005. Epub 2019 Jan 18. No abstract available.

PMID:
30665725
10.

Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment.

Zobel EH, von Scholten BJ, Goldman B, Persson F, Hansen TW, Rossing P.

Diabetes Obes Metab. 2019 May;21(5):1261-1265. doi: 10.1111/dom.13638. Epub 2019 Feb 22.

PMID:
30663196
11.

Urinary Proteomics and Precision Medicine for Chronic Kidney Disease: Current Status and Future Perspectives.

Persson F, Rossing P.

Proteomics Clin Appl. 2019 Mar;13(2):e1800176. doi: 10.1002/prca.201800176. Epub 2019 Jan 22. Review.

PMID:
30632676
12.

Cardiac ventricular sizes are reduced in patients with long-term, normoalbuminuric type 1 diabetes compared to the non-diabetic background population.

Hjortkjær HØ, Jensen T, Hilsted J, Mogensen UM, Corinth H, Rossing P, Sigvardsen PE, Fuchs A, Kühl JT, Nordestgaard BG, Køber L, Kofoed KF.

Diab Vasc Dis Res. 2019 Jan 1:1479164118819961. doi: 10.1177/1479164118819961. [Epub ahead of print]

PMID:
30599765
13.

A novel rare CUBN variant and three additional genes identified in Europeans with and without diabetes: results from an exome-wide association study of albuminuria.

Ahluwalia TS, Schulz CA, Waage J, Skaaby T, Sandholm N, van Zuydam N, Charmet R, Bork-Jensen J, Almgren P, Thuesen BH, Bedin M, Brandslund I, Christensen CK, Linneberg A, Ahlqvist E, Groop PH, Hadjadj S, Tregouet DA, Jørgensen ME, Grarup N, Pedersen O, Simons M, Groop L, Orho-Melander M, McCarthy MI, Melander O, Rossing P, Kilpeläinen TO, Hansen T.

Diabetologia. 2019 Feb;62(2):292-305. doi: 10.1007/s00125-018-4783-z. Epub 2018 Dec 13.

14.

Myocardial flow reserve assessed by cardiac 82Rb positron emission tomography/computed tomography is associated with albumin excretion in patients with Type 1 diabetes.

Zobel EH, Winther SA, Hasbak P, von Scholten BJ, Holmvang L, Kjaer A, Rossing P, Hansen TW.

Eur Heart J Cardiovasc Imaging. 2018 Dec 7. doi: 10.1093/ehjci/jey174. [Epub ahead of print]

PMID:
30535392
15.

Variations in Risk of End-Stage Renal Disease and Risk of Mortality in an International Study of Patients With Type 1 Diabetes and Advanced Nephropathy.

Skupien J, Smiles AM, Valo E, Ahluwalia TS, Gyorgy B, Sandholm N, Croall S, Lajer M, McDonnell K, Forsblom C, Harjutsalo V, Marre M, Galecki AT, Tregouet DA, Wu CY, Mychaleckyj JC, Nickerson H, Pragnell M, Rich SS, Pezzolesi MG, Hadjadj S, Rossing P, Groop PH, Krolewski AS.

Diabetes Care. 2019 Jan;42(1):93-101. doi: 10.2337/dc18-1369. Epub 2018 Nov 19.

PMID:
30455333
16.

Prevalence of heart failure and the diagnostic value of MR-proANP in outpatients with type 2 diabetes.

Jensen J, Schou M, Kistorp C, Faber J, Hansen TW, Jensen MT, Andersen HU, Rossing P, Vilsbøll T, Jørgensen PG.

Diabetes Obes Metab. 2019 Mar;21(3):736-740. doi: 10.1111/dom.13583. Epub 2018 Dec 5.

PMID:
30447033
17.

Predictive value of echocardiography in Type 2 diabetes.

Jørgensen PG, Biering-Sørensen T, Mogelvang R, Fritz-Hansen T, Vilsbøll T, Rossing P, Jensen MT.

Eur Heart J Cardiovasc Imaging. 2018 Nov 13. doi: 10.1093/ehjci/jey164. [Epub ahead of print]

PMID:
30428010
18.

Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers.

Heerspink HJL, Sjöström CD, Inzucchi SE, Hallow MK, Cain VA, Rossing P, Stefansson BV, Sartipy P.

Diabetes Obes Metab. 2019 Mar;21(3):720-725. doi: 10.1111/dom.13579. Epub 2018 Dec 11.

PMID:
30414240
19.

Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.

de Zeeuw D, Renfurm RW, Bakris G, Rossing P, Perkovic V, Hou FF, Nangaku M, Sharma K, Heerspink HJL, Garcia-Hernandez A, Larsson TE.

Lancet Diabetes Endocrinol. 2018 Dec;6(12):925-933. doi: 10.1016/S2213-8587(18)30289-4. Epub 2018 Nov 6.

PMID:
30413396
20.

Burden of Uncontrolled Metabolic Risk Factors and Left Ventricular Structure and Function in Patients With Type 2 Diabetes Mellitus.

Jørgensen PG, Jensen MT, Biering-Sørensen T, Mogelvang R, Fritz-Hansen T, Vilsbøll T, Rossing P, Jensen JS.

J Am Heart Assoc. 2018 Oct 2;7(19):e008856. doi: 10.1161/JAHA.118.008856.

Supplemental Content

Loading ...
Support Center